Canaccord Genuity maintains AbbVie at Buy, raises price target to $338 from $290

What happened

Canaccord Genuity kept its Buy rating on AbbVie and raised its price target to $338 from $290, a 16.6% increase. The new target implies 14.6% upside from AbbVie’s Oct. 30 closing price of $294.89.

Confirmed

Global impact / market context

A higher target signals that Canaccord sees more potential value in AbbVie shares, but it is an analyst estimate, not a promised return. If investors act on the revised view, buying demand could support the share price; the article provides no evidence of such a reaction.

Analyst inference

The five other recent analyst targets listed range from $275 to $325, below Canaccord’s new $338 target. This shows Canaccord is more optimistic than those listed estimates, while differing ratings—from Neutral to Overweight—show that views on AbbVie are not uniform.

Confirmed

What to watch

1. Compare future analyst targets with Canaccord’s $338 figure and the listed $275–$325 range; changes would show whether other analysts are moving toward or away from its view. Analyst inference
2. Check AbbVie’s reported business results and company guidance for evidence that could support or weaken the higher estimate; the supplied article gives no operating details. Analyst inference
3. The article reports a 14.6% implied upside from the Oct. 30 close, but gives no later share price or evidence that the target has been reached. Confirmed

Evidence

• Original source link unavailable